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ORIGINAL ARTICLE
Pseudotyping the adenovirus serotype 5 capsid with both the ﬁbre
and penton of serotype 35 enhances vascular smooth muscle cell
transduction
AL Parker1,4, KM White1, CA Lavery1, J Custers2, SN Waddington3 and AH Baker1
Ex vivo gene therapy during coronary artery bypass grafting (CABG) holds great potential to prevent excessive smooth muscle cell
(SMC) proliferation, neointima formation and graft failure. The most successful preclinical strategies to date have utilised vectors
based on the species C adenovirus, Ad5, which engages the Coxsackie and Adenovirus receptor (CAR) as its primary attachment
receptor. Proﬁling receptors on human SMCs demonstrated the absence of CAR but substantial expression of the species B receptor
CD46. We performed transduction experiments using Ad5 and the CD46-utilising adenovirus Ad35, and found Ad35 signiﬁcantly
more efﬁcient at transducing SMCs. To evaluate whether transduction could be further augmented, we evaluated chimeric
CD46-utilising Ad5/Ad35 vectors comprising the Ad5 capsid pseudotyped with the Ad35 ﬁbre alone (Ad5/F35) or in combination
with the Ad35 penton (Ad5/F35/P35). In human smooth muscle cells (hSMCs), Ad5/F35/P35 mediated signiﬁcantly higher levels
of transduction than either parental vector or Ad5/F35. Ex vivo transduction experiments using mouse aortas from CD46 transgenics
demonstrated that Ad5/F35/P35 was signiﬁcantly more efﬁcient at transducing SMCs than the other vectors tested. Finally, ex vivo
transduction and immunoﬂuorescent colocalisation experiments using human tissue from CABG procedures conﬁrmed the
preclinical potential of Ad5/F35/P35 as an efﬁcient vector for vascular transduction during CABG.
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INTRODUCTION
Cardiovascular disease remains the leading cause of mortality
worldwide, accounting for approximately one-third of global
deaths annually.1 A leading cause of cardiovascular disease is the
development of atherosclerotic plaques within the coronary
arteries. Where the plaque is stable, the condition may remain
asymptomatic for some time until the resulting vessel occlusion
becomes signiﬁcant enough to restrict blood ﬂow, depleting
oxygen and nutrient deliveries and resulting in angina pectoris.
When unstable, these plaques may rupture, resulting in
thrombosis and myocardial infarction. Coronary artery bypass
grafting (CABG) has been the mainstay clinical procedure to
alleviate the symptoms of acute coronary symptoms, whereby a
peripheral section of vasculature is utilised as a conduit to bypass
the occluded vessel. Although arterial conduits can be used for
this procedure (most commonly the left and the right internal
mammary arteries), normally autologous sections of saphenous
vein are utilised.
Following CABG, the grafted vessel undergoes a process of
remodelling its phenotype to adapt to the increased pressure and
shear rates of the arterial circulation. To achieve this, the
surrounding smooth muscle cell (SMC) layer proliferates and
expands to increase vessel plasticity. However, excessive migra-
tion and proliferation of the SMC layer can result in vessel
reocclusion (restenosis) and ultimately graft failure. Around 25%
of all grafts fail within the ﬁrst year because of thrombotic
occlusion (B10%) or intimal thickening (B15%), with a further
25% failing within 10 years because of accelerated atherosclero-
sis.2 Consequently, genetic modulation of the vasculature to
overexpress antiproliferative genes may have therapeutic beneﬁt
in preventing vein graft failure in patients undergoing CABG.
During the bypass procedure, the grafted vessel is available
outside the body forB30min prior to grafting, thus providing an
opportunity for ex vivo gene therapy. A number of potentially
therapeutic antiproliferative genes have undergone preclinical
evaluation and shown promise for their capacity to limit SMC
proliferation and neointima formation, including p53,3 NOGO-B4
and TIMP-3.5–7 To date, studies have focussed primarily on the
use of serotype 5 adenovirus (Ad5), a species C adenovirus, to
achieve overexpression of therapeutic transgene within the
vasculature;4,6–7 however, uptake of Ad5 across the vessel wall
and the resulting level of gene transfer mediated through Ad5 is
relatively poor and necessitates very high input titres (typically
41010 pfu per graft). Additionally, a signiﬁcant proportion of
patients present pre-existing neutralising antibodies against
Ad5.8–10 Collectively, these suboptimal characteristics of Ad5
could limit the progression and interpretation of vascular gene
therapy in the clinic. Efﬁcacy could be improved through
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identiﬁcation and development of more efﬁcient adenovirus-
based vectors that efﬁciently transduce the vasculature at lower,
less toxic input doses. We have therefore evaluated the expression
of known primary adenoviral receptors on cultures of human
smooth muscle cells (hSMCs) in order to rationally develop more
efﬁcacious vectors for vascular gene-transfer applications. On the
basis of our ﬁndings that Coxsackie and Adenovirus receptor
(CAR), the Ad5 receptor,11 is not expressed on hSMCs, we have
focussed our attention on Ad35-based vectors, as CD46, the
species BI Ad35 receptor,12 is expressed at high levels on hSMCs.
We therefore evaluated a panel of CD46-interacting Ad5/Ad35
chimeric vectors for their potential for vascular gene-therapy
applications using cells in culture and ex vivo gene transfer to the
vasculature. Our ﬁndings uncover a potentially important and
previously undocumented role for the Ad35 penton in enhancing
transduction of the vasculature, which may have important
translational applications for CABG.
RESULTS AND DISCUSSION
A number of previous publications have demonstrated that the
CAR-utilising species C adenovirus, serotype 5, can be efﬁcient at
transducing vascular SMCs when deployed at very high titres
(typically 41 1010 pfu per graft).13 At lower doses, the cells are
relatively refractory to Ad5 infection. We therefore sought to
evaluate whether this could be improved upon utilising
alternative species of adenovirus that utilise alternative
receptors. In order to rationally develop adenoviral vectors with
improved vascular transduction capabilities, we ﬁrst screened
cultures of hSMC to quantify the expression levels of known
adenoviral receptors on the cell surface by ﬂuorescence-activated
cell sorting (FACS). Surprisingly, we found very low levels of CAR
expression on all cultures of hSMC cells tested, with o2% of cells
staining positively for CAR expression (Figure 1). In contrast, we
found substantial expression of the species B receptor, CD46, in
cultures of hSMC cells tested, varying from 60 to 100% of cells
staining positively for expression. We also evaluated levels of
expression of the recently identiﬁed species BII receptor,
Desmoglein-2, and found that, like CAR it was not expressed on
hSMC.
Given the differential expression levels of adenoviral receptors
on primary cultures of hSMC, we rationalised that vectors based
on species B, CD46-interacting adenoviruses might be more
efﬁcacious for vascular gene-transfer applications than CAR-
utilising vectors based on Ad5. We ﬁrst performed transduction
experiments in cultures of hSMC using enhanced green-ﬂuores-
cent protein (eGFP) expressing Ad5 and Ad35 at a range of doses
from 1000 to 10 000 vp per cell. FACS analysis of transduced cells
48 h post infection demonstrated that at all doses tested, very few
hSMC cells were positive for eGFP expression when Ad5 was used
(Figure 2). However, when Ad35-eGFP was utilised, we observed a
dose-dependent increase in eGFP expression, up toB20% of cells
were positive at the highest dose tested.
Given the increased efﬁciency of vectors based on CD46-
interacting Ad35 in transducing hSMC, we next evaluated whether
chimeric Ad5/Ad35 vectors could enhance vascular transduction
further. We have previously described a panel of luciferase-
expressing adenoviral vectors comprising the parental vectors Ad5
or Ad35, or the Ad5 capsid pseudotyped with either the Ad35 ﬁbre
alone (Ad5/F35) or in combination with the penton of Ad35 (Ad5/
F35/P35), their interactions with blood-clotting factor X, and their
cell tropism and biodistribution in CD46-transgenic mice.14 In
order to assess for any additive effects of the chimeric vectors over
the parental forms in transducing hSMCs, we utilised the same
panel of vectors. To our surprise, we found that Ad5/F35/P35
reproducibly mediated higher levels of transduction in hSMC
vectors compared with either of the parental vectors or Ad5/F35
(Figure 3a). We conﬁrmed that transduction of Ad35, Ad5/F35 and
Ad5/F35/P35 was dependent on CD46 by preincubating cells with
the CD46-blocking antibody (MEM-258). The increased transduc-
tion we observed using Ad5/F35/P35 appeared to be a selective
phenomenon for hSMCs, as the same enhancements were not
observed in cultures of human endothelial cells (Figure 3c), which
demonstrated similar levels of transduction as Ad35, similarly to
several CD46-positive cancer cell lines evaluated (data not shown),
in agreement with our previous observations.14 Furthermore, we
demonstrate that these increased levels of transduction occur
within a clinically relevant time frame of 30 or 60min (Figure 3b
(hSMCs) and 3c (human endothelial cells)) and that, as expected,
levels of transduction increased with increasing exposure periods.
To investigate whether the increased transduction efﬁciency we
observed in cultures of hSMCs could be recapitulated in intact
vessels with polarised cells, we performed ex vivo transduction
experiments using aortas isolated from wild-type (MF1) or CD46-
transgenic mice. Aortas were isolated and transduced using
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Figure 1. FACS analysis to profile expression of adenoviral receptors
on cultures of hSMCs. Cultures of hSMCs were stained for the
expression of CAR (black), CD46 (green) and desmoglein-2 (purple)
using the antibodies RmcB, MEM-258 and 6D8, respectively. IgG and
unstained controls are also shown (blue and red, respectively).
Receptor expression was averaged across three samples and
quantified.
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Figure 2. Transduction of hSMCs with Ad5 and Ad35 vectors.
Cultures of hSMCs were plated to a density of 20 000 cells per well in
96-well plates and infected with 1000–10000 vp of Ad5 or Ad35
expressing eGFP. Forty-eight hours post infection, eGFP expression
was quantified using FACS. Error bars represent s.d. of three
individual samples, *Po0.01 versus Ad5.
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1 109 vp of luciferase-expressing Ad5, Ad35, Ad5/F35 or Ad5/
F35/P35. In wild-type, MF1 mice, which do not express CD46,
except in the gonads,15 Ad5 mediated the highest levels of
transduction, signiﬁcantly higher than Ad35 or either chimeric
vector (Figure 4a). However, in CD46-transgenic mice on an
MF1 background,16 Ad5/F35/P35 mediated approximately four
times higher levels of transduction than Ad35 or Ad5/F35, and
approximately eight-fold higher transduction than Ad5,
conﬁrming the importance of the presence of CD46 for the
uptake and transduction of Ad35-based vectors (Figure 4b).
As a preclinical model for therapeutic gene delivery to the
vasculature, we obtained excess human saphenous vein tissue
from CABG procedures. Samples were transduced in triplicate for
1 h at 37 1C with luciferase-expressing Ad5, Ad35, Ad5/F35 or
Ad5/F35/P35. After 48 h, luciferase expression within the vessel
was quantiﬁed. Consistent with the data obtained in cultured
hSMCs and in CD46-transgenic mouse vasculature, we observed
signiﬁcantly higher levels of transduction with Ad5/F35/P35
compared to the other vectors (Figure 5a). Coincidentally in this
model, Ad5 mediated broadly similar levels of transduction to
Ad35 (approximately four-fold lower than Ad5/F35/P35), despite
their differing receptor usage and expression levels of CAR and
CD46. To assess transgene localisation, we performed immuno-
histochemical staining on the vessels. Immunohistological analysis
of the transduced vessels (Figure 5b) clearly demonstrated the
superiority of Ad5/F35/P35 in transducing the vessel per se. To
conﬁrm expression in SMCs, an important parameter for smooth
muscle-targeted therapies, we performed immunoﬂuorescent
colocalisation experiments for luciferase and a smooth muscle
actin (Figure 5c). We observed colocalised expression in the
SMC layer in vessels transduced with Ad5/F35/P35 but not in
control vessels or those transduced with Ad5, Ad35 or Ad5/F35
(Figure 5c).
Following CABG, the grafted vessel (normally derived from the
saphenous vein) remodels in order to cope with the elevated
pressure and shear rate of the arterial circulation compared with
the lower pressure of the venous circulation from where the vessel
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Figure 3. Transduction of hSMCs and human endothelial cells (hECs)
using Ad5, Ad35 and chimeric Ad5/Ad35 vectors. Cultures of hSMC
were plated at a density of 20 000 cells per well in 96-well plates.
Cells were then incubated with CD46-blocking antibody MEM-258 or
IgG control for 1 h on ice, before being infected with 1000 vp per cell
of Ad5, Ad35, Ad5/F35 or Ad5/F35/P35 expressing luciferase for 1 h.
After 1 h, media was removed; the cells were cultured for a further
48 h in complete media before the analysis of luciferase transgene
expression was performed. *Po0.01 versus Ad5, $Po0.01 versus
Ad35, #Po0.01 versus IgG-blocking control (a). Cultures of hSMCs (b)
or hECs (c) were transduced with 1000 vp per cell of Ad5, Ad35, Ad5/
F35 or Ad5/F35/P35 for 30min or 1 h, before media was removed;
the cells were cultured for a further 48 h in complete media before
the analysis of luciferase transgene expression was performed.
*Po0.05 increased versus Ad5, $Po0.05 increased versus Ad35. Error
bars represent s.d. of three individual samples.
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Figure 4. Ex vivo transduction in intact mouse vasculature. Aortas
were isolated from MF1 mice (a) or CD46-transgenic mice (b) and
divided into three equally sized pieces. The tissue was then
incubated in 500 ml of serum-free media containing 1 109 vp of
Ad vector. After 1 h of incubation, tissue was cultured for a further
48 h. The vessels were then subject to bioluminescence quantifica-
tion imaging, with transduction expressed as average radiance
(p s 1 cm 2 sr 1). *Po0.05 versus Ad5, #Po0.05 versus Ad35.
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Figure 5. Ex vivo transduction in the intact human saphenous vein. Saphenous vein from bypass grafting procedures were divided into
sections of 5–6mm in length and incubated in 500 ml of serum-free media containing 1 1010 vp of Ad vector. After 1 h of incubation, tissue
was cultured for a further 48 h in complete media. The vessels were then subjected to bioluminescence quantification imaging, with
transduction expressed as average radiance (p s 1 cm 2 sr 1) (a). *Po0.01 versus Ad5. Luciferase expression was detected histologically in
frozen sections using a luciferase primary antibody (or IgG control) and a HRP-conjugated secondary antibody, and staining compared with
von Willebrand factor (to detect endothelial cells). Representative images are shown, magnification  40. (b) Luciferase expression (green)
was detected histologically in frozen sections using a luciferase primary antibody (or IgG control), and colocalistion (yellow) was determined
with the smooth muscle cell marker, a-smooth muscle actin (red). Representative images are shown, magnification  25 (except zoomed
image,  40) (c).
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was derived (reviewed in McDonald et al.17) The remodelling
process necessitates the migration and proliferation of vascular
smooth muscle cells to increase vessel plasticity; however, this
may result in neointima formation and subsequent vessel
reocclusion. Vessel reocclusion following engraftment represents
a major limitation of bypass graft surgery, contributing
signiﬁcantly to a cumulative graft failure rate of B50% within
10 years post surgery.2 A potential means to limit proliferation and
thus prevent graft failure is by performing ex vivo gene therapy to
deliver antiproliferative genes to the conduit during the grafting
procedure (overviewed in Robertson et al.18). To this end, we
have demonstrated potential for a number of therapeutic
antiproliferative genes including NOGO-B,4 p533,19 and TIMP-36–7
in preventing vessel reocclusion using preclinical models in mice
and pigs. To achieve therapeutic levels of transgene expression,
we have utilised high-concentration adenoviruses based on
serotype 5. In vitro, and for local gene-therapy applications
in vivo, Ad5 binds to cells predominantly through the primary
interaction with the CAR11,20 and internalisation through integrin
engagement.21 We have found that efﬁcient transduction of the
vasculature requires very high input of Ad5, typically 41010 pfu
per graft. Given the potential for dose-limiting toxicities at such
high doses and the very high levels of pre-existing immunity
against Ad5 in the general population, we reasoned that the
development of more efﬁcacious vectors that transduce the
vasculature efﬁciently at lower doses during the clinical window of
opportunity for ex vivo gene therapy during bypass grafting may
be advantageous in the clinical setting.
Our observation that cultures of hSMC express vanishingly low
levels of the Ad5 receptor CAR may explain the requirement for
extremely high doses of Ad5 to efﬁciently transduce hSMCs. It is
possible that at such high titres, engagement of secondary
receptors, namely the integrin avb3 and avb5, which are
expressed at high levels on hSMCs,2 may mediate the uptake of
Ad5. We observed similarly low levels of the recently identiﬁed
species BII receptor desmoglein-2, the cellular receptor for Ad3, 7,
11 and 14.3 Given the high levels of expression of the species B
receptor CD46 observed in all cultures tested, we rationalised that
adenoviral vectors based on CD46-interacting species of
adenovirus might be better suited to translational CABG gene-
transfer applications. We therefore focussed our study on the
potential of Ad35, a serotype well known to utilise CD46 as its
primary cellular receptor,12,24–26 to deliver reporter genes to
cultures of hSMCs in vitro. At all doses tested, we found that Ad35
was more efﬁcient at transducing hSMCs than Ad5. Evaluating the
effects of capsid pseudotyping on transduction efﬁciency of
cultured hSMCs demonstrated that all viruses pseudotyped
with the Ad35 ﬁbre transduced cells in a CD46-dependent manner.
Unexpectedly, we noted that the additional pseudotyping of the
Ad35 penton into the Ad5 capsid had a beneﬁcial effect on
transduction, enhancing transduction of hSMCs by greater than
three-fold and approximately ten-fold relative to Ad5/F35.
Interestingly, this enhancing effect on transduction appeared
selective for SMCs, as transduction experiments in cancer cell lines
showed no additional augmentation of transduction (data not
shown).
Given that CD46 is expressed at high levels on cultures of
hSMCs (and that CAR is not), and the additional beneﬁcial effects
on transduction of pseudotyping the Ad5 capsid with both the
ﬁbre and penton from Ad35, we performed preclinical studies
using intact vessels. This is potentially important because
de-differentiation of cells in vitro is a well-characterised phenom-
enon,27–28 and in vitro culture systems are often unable to
reproduce the polarised phenotype of cells in vivo. This may result
in potentially promising in vitro results failing to reproduce in vivo,
as the receptors are not accessible from the appropriate
compartment (that is, the luminal surface) in intact vessels.
Systems that work well in vitro but fail through polarisation and
inaccessibility of receptors in vivo are well known in gene
therapy.29 We therefore performed studies in intact mouse
vessels from wild-type (MF1) and CD46-transgenic mice, as
murine expression of CD46 is limited to the testes,15 whereas
CD46 is expressed ubiquitously in the human. In aortas derived
from MF1 mice, Ad5 mediated signiﬁcantly higher levels of
transduction than any of the CD46-utilising Ads. However, in the
CD46-transgenic mouse, we observed the highest levels of
transduction using Ad5/F35/P35, consistent with our in vitro
observations, whereas both Ad35 and Ad5/F35 mediated
signiﬁcantly higher levels of transduction than Ad5.
Furthermore, in ex vivo transduction experiments using excess
residual clinical material from coronary artery bypass procedures,
we again noted that Ad5/F35/P35 mediated higher levels of
transduction than any other virus tested, mediating approximately
four-fold higher transduction than either parental vector Ad5 or
Ad35, gauged by IVIS imaging. Importantly, as the vessel
comprises multiple cell types, we conﬁrmed the presence of
transgene expression in SMCs using immunoﬂuorescence and
demonstrated that Ad5/F35/P35 was the only vector that
efﬁciently transduced this cell type at the doses tested.
Taken together, our data suggest that vectors based on species
B, CD46-interacting adenoviruses likely hold greater potential for
translational CABG gene-therapy applications than species C, CAR-
interacting adenoviruses. We also identify an additional role for
the Ad35 penton in enhancing transduction of Ad5/F35-pseudo-
typed vectors in hSMCs; however, the precise role of the penton in
this context remains unclear but likely relates to improved uptake
(compared with Ad5) and intracellular trafﬁcking (compared with
Ad35) in hSMCs.
MATERIALS AND METHODS
Cell culture
Human SMCs and ECs were prepared using residual tissue from CABG
procedures as described previously.30,31 Informed consent and ethics
approval were obtained prior to this procedure. SMCs were maintained in
SMC growth media 2 (Promocell, Heidleberg, Germany) containing 15%
fetal calf serum (FCS) and passaged for a maximum of six times. ECs were
maintained in Large Vessel Endothelial Cell Basal Medium (TCS CellWorks,
Buckingham, UK) containing 20% FCS. Other cell lines utilised were
cultured in RPMI media containing 10% FCS and maintained at 37 1C and
5% CO2.
FACS analysis of adenoviral receptors expressed on hSMCs
Cells were resuspended to a density of 2 105 cells per tube in 50 ml of
cold serum-free media and incubated with 50 ml SF media containing
1/250 v/v (ﬁnal concentration thus 1/500) of mouse antihuman
monoclonal antibody against CAR (RmcB, Millipore, Watford, UK), CD46
(MEM-258, Abcam, Cambridge, UK) Desmoglein-2 (6D8, Hycult biotech,
Uden, The Netherlands) or mouse IgG control antibody (Invitrogen, Paisley,
UK) for 30min on ice. Cells were washed in 4ml PBS and centrifuged
(1000 r.p.m., 5min, 4 1C). PBS was discarded, and cells were incubated with
1:250 dilution of goat anti-mouse Alexa Fluor 488 (Invitrogen) secondary
antibody in serum-free media for 30min on ice. Alexa Fluor-488
ﬂuorescently labelled cells were detected using a FACS Canto II ﬂow
cytometer (Beckton Dickinson, Oxford, UK) and FACS DIVA software. Viable
cells were gated on the basis of forward and side scatter proﬁles, with a
minimum of 10 000 gated events analysed per sample. Results are
expressed as percentage of positive cells per condition. For each condition,
a minimum of three separately treated samples were analysed and an
average was taken.
Adenovirus production, puriﬁcation and quality control
All viruses described in this manuscript are ﬁrst-generation, replication-
incompetent E1-deleted vectors, propagated in the E1-complementing cell
line 293 cells. Virus was puriﬁed using standard CsCl gradients and kept for
long-term storage in 10% Glycerol, and 90% TE buffer. Viral recovery was
quantiﬁed by microBCA assay using the following equation: 1 mg
protein¼ 4 109 viral particles (vp). Infectious units (pfu) were quantiﬁed
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by end point dilution plaque assay on 293 permissive cells using the
standard protocols. Physical particle titres for Ad5, Ad35, Ad5/F35 and
Ad5/F35/P35 were 2.70 1012, 8.00 1012, 5.07 1012 and 2.70 1012,
respectively, whereas infectious particle titres were 2.60 1010, 4.77 1010,
1.50 1010 and 2.95 109, respectively, resulting in vp:pfu ratios of 104,
168, 338 and 915, respectively. As toxicity in vivo is determined by the
physical particle load rather than infectious units, we standardise all our
experiments to vp.
In vitro transduction
A total of 2 104 cells per well were washed with PBS before the addition of
1000–10000 vp per cell Ad-expressing luciferase in 50ml of serum-free media
for 3 h at 37 1C. Media were discarded and replaced with complete media
and incubated at 37 1C for a further 45h. Cell lysate was generated by the
addition of 100ml 1 reporter lysis buffer (RLB, Promega, Warrington, UK)
per well, followed by freeze/thawing prior to the analysis of reporter gene
activity. Luciferase activity in the resulting lysate was quantiﬁed by the
addition of 100ml luciferase assay substrate (Promega) to 10ml of cell lysate
diluted with 90ml RLB. Luciferase activity was quantiﬁed using a Wallac
VICTOR2 plate reader (PerkinElmer Life and Analytical Sciences, Boston MA,
USA) and normalised to total protein content of the samples, measured by
bicinchoninic acid assay as per the manufacturer’s instructions, producing
relative light units per milligram protein (RLUmg 1 protein).
Ex vivo transduction of vessels
Mouse aorta were isolated from either MF1 wild-type mice or CD46-
transgenic on an MF1 background and divided into three equally sized
pieces. The tissue was washed in PBS and incubated in 500ml of serum-free
media containing 1 109 vp of vector. After 1 h of incubation, media was
discarded and cultured in EMEM containing 20% FCS for a further 2 days. For
studies involving intact human vessel, excess material from CABG procedures
was trimmed to remove excess periadventitial fat and was divided into
equally sized sections ofB5mm width and placed into a 24-well plate. The
vessel was incubated with 500ml of serum-free media containing 1 1010 vp
of vector. After 1 h of incubation, the media containing virus was discarded,
then tissue was washed with PBS and cultured in SMC growth media
containing 15% FCS for a further 2 days at 37 1C and 5% CO2. Following 48h
in culture, the transduced vessels were subject to bioluminescence
quantiﬁcation imaging (IVIS Spectrum, Caliper Life Sciences, Hopkinton,
MA, USA). Luciferin activity was measured using the IVIS Imaging System
(IVIS Spectrum, Caliper), and transduction is expressed as average
radiance (photons per second per centimetre squared per steradian
(p s 1 cm 2 sr 1)).
Immunohistological/immunoﬂuorescent detection of luciferase
expression in human vessels
Immunohistochemistry was performed on 6 mm frozen sections with
mouse anti-luciferase antibody (Luci17; Santa Cruz Biotechnology, Heidel-
berg, Germany), rabbit anti-von Willebrand Factor (A0082; Dako, Glostrup,
Denmark) or the appropriate IgG control (Dako). Sections were ﬁxed with
ice-cold acetone and then treated with 3% hydrogen peroxide to inhibit
endogenous peroxidase activity. Sections were blocked in 10% serum and
then treated with avidin/biotin kit (Vector Laboratories, Peterborough, UK).
For detection, the appropriate biotinylated secondary antibody (Dako) and
ExtrAvidin-Peroxidase (SigmaAldrich, Suffolk, UK) were used. Staining was
visualised using 3’,3’-diaminobenzidine tetrahydrochlorate dihydrate and
hydrogen peroxide. Sections were counterstained with haematoxylin.
Immunoﬂuorescence was performed on 6 mm frozen sections with
mouse anti-luciferase antibody, rabbit anti-a smooth muscle actin (ab5694;
Abcam) or the appropriate IgG control (Dako). Sections were ﬁxed with ice-
cold acetone, and then antigen retrieval was performed by heating in
10mM sodium citrate buffer (pH 6). Sections were blocked in 10% goat
serum. For detection, goat anti-mouse alexa546 and goat anti-rabbit
alexa647 (Invitrogen) were used. Slides were mounted in ProLong Gold
Antifade Reagent with DAPI (Invitrogen). Images were acquired using a
Zeiss LSM510 confocal imaging system using LSM image acquisition
software (Carl Zeiss, Welwyn Garden City, UK).
Statistics
Results presented are representative data from a minimum of three separate
experiments with at least three experimental replicates per group, unless
otherwise stated. Statistical signiﬁcance was calculated using two-sample,
two-tailed Student’s t-tests. Po0.05 was considered statistically signiﬁcant.
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